Legal & General Group PLC Verastem, Inc. Transaction History

Legal & General Group PLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 22, 2022	SELL	$1.02 - $1.83 $18,883 - $33,878	-18,513 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.05 - $3.2 $516 - $806	252 Added 1.38%	18,513 $38,000
Q2 2021 Aug 12, 2021	BUY	$2.57 - $4.85 $5,600 - $10,568	2,179 Added 13.55%	18,261 $74,000
Q1 2021 May 17, 2021	SELL	$1.9 - $2.82 $1,592 - $2,363	-838 Reduced 4.95%	16,082 $40,000
Q3 2020 Nov 13, 2020	SELL	$1.11 - $1.68 $7,119 - $10,775	-6,414 Reduced 27.49%	16,920 $20,000
Q2 2020 Aug 14, 2020	BUY	$1.69 - $4.2 $39,434 - $98,002	23,334 New	23,334 $40,000
Q3 2019 Nov 13, 2019	SELL	$1.21 - $1.59 $12,463 - $16,377	-10,300 Closed	0 $0
Q3 2018 Nov 20, 2018	BUY	$6.86 - $9.97 $16,628 - $24,167	2,424 Added 30.78%	10,300 $75,000
Q2 2018 Aug 10, 2018	BUY	$2.88 - $8.67 $22,682 - $68,284	7,876 New	7,876 $54,000

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $1.13B
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.